TP53 and ovarian carcinoma: This might imply that the loss of p53 function mediated by p53null mutations induces acquired resistance to carboplatin by accumulating cells in the G2/M phase of the cell cycle, rendering these cells with more stem-like features to evade the apoptotic pathway, which is not applicable for p53-expressing mutations harboring ovarian cancers.